Sudeep Pharma IPO Details: Price, Dates & Financials

Sudeep Pharma reports PAT margin 27.63% and EBITDA margin 39.70%.

The debt-to-equity ratio of Sudeep Pharma is 0.20. A lower ratio generally means the company relies less on borrowed money.

The price-to-book value (P/BV) of Sudeep Pharma IPO is 12.93.

ROE (return on equity) shows profit earned on shareholders' money, ROCE (return on capital employed) shows profit earned on all capital used in the business, and RONW (return on net worth) measures return on the company's net worth. Higher figures usually indicate more efficient use of capital.

Compare ROE, ROCE, margins and P/BV of Sudeep Pharma with listed companies in the same sector, and check the peer comparison given in the offer document. Ratios are only one input — they do not predict listing gains.

We require these key ratios to evaluate the financial health, profitability, valuation, and overall performance of the Sudeep Pharma IPO. They help investors understand how efficiently the company operates, how much debt it carries, and whether its shares are reasonably valued compared with its earnings and assets for that specific Sudeep Pharma IPO. These ratios also help assess the Sudeep Pharma IPOs ability to generate profits, manage financial obligations, and deliver sustainable growth, enabling investors to make a more informed Sudeep Pharma IPO investment decision.

Investors should examine the Sudeep Pharma IPO's revenue growth, profitability, debt levels, cash flow, and earnings per share (EPS). These indicators help assess the Sudeep Pharma IPO's financial stability, growth potential, and investment risks before investing in the Sudeep Pharma IPO.